Clinical trial
Preventing ESRD in Overt Nephropathy of Type 2 Diabetes
NCT00494715 · Mario Negri Institute for Pharmacological Research, Other · Completed
Key facts
| NCT number | NCT00494715 |
|---|---|
| Title | Preventing ESRD in Overt Nephropathy of Type 2 Diabetes |
| Official title | A Prospective, Randomized, Probe Trial to Evaluate Whether,at Comparable Blood Pressure Control,Combined Therapy With ACEI BEN and ARB VAL Reduces Progression to ESRD More Effectively Than BEN or VAL Alone in High Risk Patients With Type 2 Diabetes and Overt Nephropathy |
| Acronym | VALID |
| Lead sponsor | Mario Negri Institute for Pharmacological Research, Other |
| Collaborators | Agenzia Italiana del Farmaco |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes |
| Intervention type | Drug |
| Interventions | Benazepril, Valsartan, Benazepril/Valsartan |
| Enrollment | 102 |
| Start date | May 1, 2007 |
| Primary completion | Apr 1, 2016 |
| Completion | Apr 1, 2016 |
| First posted | Jul 2, 2007 |
| Last update posted | Jun 1, 2016 |
| Countries | Italy, Slovenia |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: